Drivers of Change

• Significant expansion of involvement along entire value chain, especially in access arena

• Collaboration imperative

• COVID-19 pandemic – impact and lessons learned

• TB therapy endgame
Advancing Access to New Treatments

TB Alliance and partners have significantly accelerated global approval and access

• **Approved** by 16 regulatory authorities including the U.S. FDA and European Commission (total of ~45 countries)

• Pretomanid **WHO prequalified** in 2020 and recommended in **WHO Treatment Guidelines** under operational research conditions

• **Operational Research programs** are ongoing or imminent in at least 14 countries

• Over 4000 treatment courses delivered

• Available globally through Viatris’ **Named Patient Access Program**

• Listed in the Stop TB Partnership’s **Global Drug Facility** – ensures availability in over 150 low- and middle-income countries
MOBILIZING

a global network of partners
COVID-19 Has Disrupted Public Health

Number of deaths worldwide per year

- TB: 1.5 million
- HIV/AIDS: 1 million
- COVID-19: 2.75 million

COVID-19 pandemic has also set back progress against TB
Key Lessons Learned from COVID-19 Pandemic

Pandemics (old and new) require innovative new tools

• Transformative power of science when adequately funded - COVID-19 has shown that impactful new tools (diagnostics, vaccines, and drugs) can be developed quickly with adequate funding and political will

• Requirement for universal access in order to maximally benefit from scientific advances
TB Therapy Endgame

Drug-Susceptible TB
- Past: 6 months
- Present: 4 months
- A Funded Future: 7-10 days

Drug-Resistant TB
- Past: 18+ months
- Present: 6 months
Thank You